Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2026)
Vivos Therapeutics (VVOS) reported EBITDA Margin of 122.84% for Q1 2026, up 44.0% year-over-year from 85.3% in Q1 2025, and up 28.63% on a QoQ basis from 172.12% in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of EBITDA Margin data on file, last reported at 122.84% in Q1 2026.
- Quarterly EBITDA Margin rose 44.0% year-over-year to 122.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 111.39% (down 3752.0% YoY) and the FY2025 annual result came in at 110.04%, down 3905.0% from the prior year.
- EBITDA Margin rose to 122.84% in Q1 2026 per VVOS's latest filing, from 172.12% in the prior quarter.
- Across five years, EBITDA Margin topped out at 45.29% in Q2 2024 and bottomed at 176.7% in Q1 2022.
- The 5-year median for EBITDA Margin is 122.63% (2022), against an average of 116.69%.
- The widest annual swing landed in 2022, when EBITDA Margin slumped 34640 bps; it then surged 8481 bps in 2024.
- Tracing VVOS's EBITDA Margin over 5 years: stood at 145.9% in 2022, then grew by 17 bps to 121.09% in 2023, then soared by 40 bps to 73.17% in 2024, then plunged by 135 bps to 172.12% in 2025, then advanced by 29 bps to 122.84% in 2026.
- Per Business Quant, the three latest VVOS EBITDA Margin figures stand at 122.84% (Q1 2026), 172.12% (Q4 2025), and 63.9% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 14.52% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.94% |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | -122.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -122.84% |
| Dec 31, 2025 | -172.12% |
| Sep 30, 2025 | -63.90% |
| Jun 30, 2025 | -119.50% |
| Mar 31, 2025 | -123.28% |
| Dec 31, 2024 | -73.17% |
| Sep 30, 2024 | -65.93% |
| Jun 30, 2024 | -45.29% |
| Mar 31, 2024 | -107.78% |
| Dec 31, 2023 | -121.09% |
| Sep 30, 2023 | -107.24% |
| Jun 30, 2023 | -130.10% |
| Mar 31, 2023 | -124.58% |
| Dec 31, 2022 | -145.90% |
| Sep 30, 2022 | -122.63% |
| Jun 30, 2022 | -161.66% |
| Mar 31, 2022 | -176.70% |
| Dec 31, 2021 | 200.50% |
| Sep 30, 2021 | -118.85% |
| Jun 30, 2021 | -88.51% |
| Mar 31, 2021 | -95.88% |
| Dec 31, 2020 | -189.37% |
| Sep 30, 2020 | -50.28% |
| Jun 30, 2020 | -41.01% |
| Mar 31, 2020 | -77.63% |